The Drug Target Everyone Gave Up On Just Won Again

That "regardless" part matters enormously. COPD is overwhelmingly a smoker's disease, but treatments that only work in specific patient subgroups have limited commercial appeal. Tozorakimab doesn't seem to care whether you quit smoking 20 years ago or last Tuesday.

The safety profile? Clean and consistent across all three studies. No red flags.

Why Everyone Else Struck Out

To appreciate what AstraZeneca pulled off, you need to understand the wreckage it navigated around.

Roche's astegolimab went down in Phase 3 for COPD. Full stop. The drug blocked IL-33 signaling but couldn't get the job done in patients.

Sanofi and Regeneron's itepekimab had a messier ending. Their first Phase 3 COPD trial (Aerify-1) actually worked, showing a 27% reduction in exacerbations at the higher dose. But the second trial (Aerify-2) essentially flatlined, producing only a 2% reduction. When your two pivotal trials contradict each other that badly, the FDA tends to raise an eyebrow. Analysts suggested the companies might need to run a third Phase 3 study, adding years and hundreds of millions in costs.

Sanofi also gave up on combining itepekimab with Dupixent in asthma after a Phase 2 trial showed the combo added zero benefit. The ripple effects were brutal: even AnaptysBio, a smaller company working on IL-33, saw its shares tank 16% on the news.

By late 2025, the consensus was clear. IL-33 was a graveyard target. Move along.

AstraZeneca Didn't Get the Memo

Instead of retreating, AstraZeneca doubled down. The company had already posted wins in its OBERON and TITANIA trials, and MIRANDA confirmed the pattern.

Three trials. Three wins. Consistent results across different patient populations.

Jefferies analyst Michael Leuchten pointed out that tozorakimab could potentially double the eligible population for COPD biologics to nearly 80% of exacerbation-prone patients. That's because Dupixent (the current heavy hitter in the space) is largely restricted to patients with high eosinophil levels, a specific type of white blood cell. Tozorakimab works across eosinophil levels, which dramatically widens the net.

GlobalData analyst Vinie Varkey echoed the optimism, noting that the drug's efficacy across both eosinophil levels and smoking status positions it for "significant patient share" as an add-on therapy.

Follow the Money

AstraZeneca is projecting $3 to $5 billion in peak annual sales for tozorakimab. That's not a rounding error; it's a franchise. The company has woven this drug into its broader goal of reaching $80 billion in total revenue by 2030.

The addressable market is massive, and right now there aren't many biologics competing for these patients. Dupixent is the main rival, along with GSK's Nucala and a handful of earlier-stage programs.

If tozorakimab gets approved with a broad label (meaning doctors can prescribe it for COPD patients regardless of biomarker status), it won't just compete with existing biologics. It will create a new category of patients who finally have a biologic option at all.

AstraZeneca is also running tozorakimab in Phase 3 for severe viral lower respiratory disease and Phase 2 for asthma, so the COPD story might just be the opening act.

The Bigger Picture

Drug development is full of targets that looked promising, attracted a stampede of companies, and then collapsed when the Phase 3 data came in. When that happens, the entire industry tends to walk away. It's rational. It's also sometimes wrong.

AstraZeneca's IL-33 story is a reminder that how you hit a target matters as much as which target you hit. Blocking both forms of IL-33, targeting multiple downstream pathways (including ones involved in mucus production and lung remodeling): these molecular details sound academic until they're the difference between a $5 billion drug and an expensive failure.

The company plans to file for regulatory approval and present full data at an upcoming medical congress. If approvals go smoothly, tozorakimab could become the first-in-class IL-33 biologic to reach patients.

For the millions of people with COPD who cycle through inhaler after inhaler without relief, that fire alarm might finally get unstuck.

The $700M Biotech That Got Rejected by Wall Street Is Back for Round Two

Odyssey Therapeutics got rejected by Wall Street in 2025 when it pulled its IPO amid a frozen biotech market. Now it's back with $700 million in venture backing and a new S-1 filing, testing whether the 2026 recovery is real.